|
Rumination Disorders
|
0.010 |
GeneticVariation
|
group |
BEFREE |
While no genome-wide significant hit emerged at the SNP level, the association of rumination survived correction for multiple testing with KCTD12 at the gene level, and with the set of genes binding miR-383 at the gene set level.
|
30886212 |
2019 |
|
ovarian neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
Therefore, miR-383-5p/TRIM27 axis may be the potential target for the treatment of ovarian cancer.
|
30399596 |
2019 |
|
Malignant neoplasm of ovary
|
0.010 |
Biomarker
|
disease |
BEFREE |
Therefore, miR-383-5p/TRIM27 axis may be the potential target for the treatment of ovarian cancer.
|
30399596 |
2019 |
|
Nasopharyngeal carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Besides, high mobility group AT-hook 2 (HMGA2) was proved to be a target of miR-383-3p in NPC.
|
30536950 |
2019 |
|
Triple Negative Breast Neoplasms
|
0.010 |
Biomarker
|
disease |
BEFREE |
LINC00096 Promotes the Proliferation and Invasion by Sponging miR-383-5p and Regulating RBM3 Expression in Triple-Negative Breast Cancer.
|
31819536 |
2019 |
|
Triple-Negative Breast Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
LINC00096 Promotes the Proliferation and Invasion by Sponging miR-383-5p and Regulating RBM3 Expression in Triple-Negative Breast Cancer.
|
31819536 |
2019 |
|
Cardiovascular Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
These findings highly indicate that miR-383-3p may be beneficial in the prevention of CAS and other cardiovascular diseases.
|
29693751 |
2018 |
|
Cholangiocarcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In conclusion, miR-383 serves as a tumor-suppressive miR to regulate cholangiocarcinoma cell proliferation, migration, and invasion via directly targeting IRF1.
|
30145803 |
2018 |
|
Memory impairment
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
The present study aimed to investigate the effect of microRNA-383 (miR-383) expression on propofol-induced learning and memory impairment.
|
29545833 |
2018 |
|
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
An MTT assay was used to examine the function of miR-383 and ZEB2 in MALT lymphoma.
|
29387204 |
2018 |
|
Impaired cognition
|
0.010 |
Biomarker
|
disease |
BEFREE |
The present study suggested that miR-383 may be used as a potential therapeutic target for the clinical treatment of cognitive impairment induced by propofol anesthesia.
|
29545833 |
2018 |
|
Forgetful
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
The present study aimed to investigate the effect of microRNA-383 (miR-383) expression on propofol-induced learning and memory impairment.
|
29545833 |
2018 |
|
Apraxia, Developmental Verbal
|
0.010 |
Biomarker
|
disease |
BEFREE |
Hence, this study aims to explore the function of miR-383-3p targeting IL1R2 on inflammatory injury of coronary artery endothelial cells (CAECs) in CAS.
|
29693751 |
2018 |
|
Progression of non-small cell lung cancer
|
0.010 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to investigate the roles of microRNA-383 (miRNA-383) in progression of non-small cell lung cancer (NSCLC) and the potential mechanism.
|
30426539 |
2018 |
|
Familial primary gastric lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
An MTT assay was used to examine the function of miR-383 and ZEB2 in MALT lymphoma.
|
29387204 |
2018 |
|
Malignant neoplasm of thyroid
|
0.010 |
Biomarker
|
disease |
BEFREE |
However, the function and mechanism underlying the action of miR-383-3p in thyroid cancer remain unclear and were therefore investigated in this study by <i>in vitro</i> and <i>in vivo</i> experiments.
|
28560065 |
2017 |
|
Obesity
|
0.010 |
Biomarker
|
disease |
BEFREE |
Role of miR-383 and miR-146b in different propensities to obesity in male mice.
|
28576870 |
2017 |
|
Thyroid Neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
However, the function and mechanism underlying the action of miR-383-3p in thyroid cancer remain unclear and were therefore investigated in this study by <i>in vitro</i> and <i>in vivo</i> experiments.
|
28560065 |
2017 |
|
Adenocarcinoma of lung (disorder)
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, the results of the present study demonstrated that miR-383-5p was downregulated in LAC tissues.
|
28927114 |
2017 |
|
Gastric Adenocarcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
MiR-383 was dramatically downregulated up to sevenfold in intestinal-type gastric adenocarcinoma compared with adjacent tumor-free tissues (P < 0.001).
|
28243881 |
2017 |
|
Thyroid carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
However, the function and mechanism underlying the action of miR-383-3p in thyroid cancer remain unclear and were therefore investigated in this study by <i>in vitro</i> and <i>in vivo</i> experiments.
|
28560065 |
2017 |
|
Tumor Initiation
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
In view of our results, we propose that frequent loss of miR-383 at chr8p22 region leads to tumor initiation and prostate cancer metastasis.
|
27893706 |
2017 |
|
Carcinoma
|
0.010 |
Biomarker
|
group |
BEFREE |
In clinical samples, miR-383 was also found to be markedly downregulated in NSCLC carcinomas than in non-carcinoma lung tissues, and in advanced-stage carcinomas than in early-stage carcinomas.
|
27551765 |
2016 |
|
Epithelial ovarian cancer
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In stably miR-383-downregulated EOC cell lines, cancer proliferation, cell cycle progression, invasion and in vivo explant development were significantly suppressed.
|
27567588 |
2016 |
|
Medulloblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In this study, we demonstrated significant downregulation of miR-383 in 23/29 (79%) MB samples and 7/7 (100%) MB cells lines.
|
23227829 |
2013 |